Analgesic Effect of Buprenorphine for Chronic Noncancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Pooled result · Pain scoreResult — go to the resultSMD −0.368Authors' conclusion
Buprenorphine was associated with a statistically significant and small reduction in pain intensity compared to placebo.
Study context
- Population
- Patients with chronic noncancer pain without opioid use disorder (OUD)14 RCTs
- Comparison
- Buprenorphine vs placebo or active analgesic
- Outcome
- Pain intensity (SMD in pain score)
Methodological detailsrandom-effects model, Grade of Recommendations Assessment, Development, and Evaluation (GRADE) assessment, Only one study met the search criteria for patients with OUD, Quality of evidence low to moderate (GRADE)
- Random-effects model
- GRADE assessment
- Only one study met the search criteria for patients with OUD
- Quality of evidence low to moderate (GRADE)
Pooled result
Pain score
SMD
−0.368
P < 0.001
As reported in the abstract
Further pooled results
| Outcome | SMD | P value |
|---|---|---|
| Pain score, vs placebo (subgroup) | −0.404 | P < 0.001 |
| Pain score, vs active analgesic (subgroup)No significant difference | 0.045 | P > 0.05 |
| Pain score, chronic low back pain (subgroup) | −0.383 | P < 0.001 |
| Pain score, transdermal route (subgroup) | −0.572 | P = 0.001 |
| Pain score, buccal route (subgroup) | −0.453 | P < 0.001 |
| Pain score, follow-up <12 weeks (subgroup) | −0.848 | P < 0.05 |
| Pain score, follow-up 12 weeks or more (subgroup) | −0.415 | P < 0.001 |
Original publication
Analgesic Effect of Buprenorphine for Chronic Noncancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesth Analg. Published 16 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →